| 2024-11-12 | -1.13 % |
|
| 2024-11-08 | -0.75 % |
|
| 2024-11-01 | +2.12 % |
|
| 2024-10-31 | -0.78 % |
|
| 2024-10-30 | +0.52 % |
|
| 2024-10-29 | -0.86 % |
|
| 2024-10-28 | -0.33 % |
|
| 2024-10-25 | -0.54 % |
|
| 2024-10-24 | -3.31 % |
|
| 2024-10-23 | -1.69 % |
|
| 2024-10-22 | -1.51 % |
|
| 2024-10-17 | +1.3 % |
|
| 2024-10-16 | -1.49 % |
|
| 2024-10-15 | -0.54 % |
|
| 2024-10-14 | +1.15 % |
|
| 2024-10-11 | +0.53 % |
|
| 2024-10-10 | -0.91 % |
|
| 2024-10-09 | +0.64 % |
|
| 2024-10-08 | -0.57 % |
|
| 2024-10-07 | +0.04 % |
|
| 2024-10-03 | -1.93 % |
|
| 2024-10-02 | -0.04 % |
|
| 2024-10-01 | -0.91 % |
|
| 2024-09-30 | +0.68 % |
|
| 2024-09-27 | -0.79 % |
|
| 2024-09-26 | +3.26 % |
|
| 2024-09-25 | -1.98 % |
|
| 2024-09-24 | +0.25 % |
|
| 2024-09-23 | -0.54 % |
|
| 2024-09-20 | -1.06 % |
|
| 2024-09-19 | +1.66 % |
|
| 2024-09-17 | -0.6 % |
|
| 2024-09-04 | +0.9 % |
|
| 2024-08-30 | +0.55 % |
|
| 2024-08-09 | -0.64 % |
|
| 2024-08-01 | +1.37 % |
|
| 2024-07-24 | +4.07 % |
|
| 2024-07-17 | -0.06 % |
|
| 2024-07-11 | +1.08 % |
|
| 2024-06-28 | +0.4 % |
- The article discusses how Thermo Fisher Scientific (TMO) stock increased by 0.4% last night, and the reason for this rise could be attributed to positive market sentiment towards the company's performance and potential earnings growth.
- The article discusses the broadcasting of New to the Street TV show on Bloomberg TV featuring interviews with various companies, including Hapbee Technologies, Inc., Banzai International, Inc., Zapp Electric Vehicles Group Limited, Karma Water, Sustainable Green Team, Ltd., and Sekur Private Data Ltd., which may have contributed to Thermo Fisher Scientific (TMO) stock going up due to positive investor sentiment towards these companies.
|
| 2024-06-26 | +0.3 % |
- Thermo Fisher Scientific (TMO) stock went up by 0.3% last night, likely due to the completion of the tax-free spin-off of GRAIL, Inc. by Illumina, Inc. This spin-off will allow Illumina to focus on its core business of consumables, instruments, and services, while GRAIL, Inc. will operate independently in the early cancer detection market with its Galleri test, providing both companies with unique investment opportunities and potential for growth.
- The article discusses a study on the regulation of Plasmodium falciparum virulence gene expression through RNA polymerase III (RNA Pol III) inhibition, identifying Maf1 as a key regulator, and how this mechanism may contribute to the occurrence of seasonal asymptomatic malaria infections; the study found that RNA Pol III-transcribed genes were significantly downregulated in parasites from asymptomatic infections during the dry season compared to symptomatic infections during the wet season, potentially impacting Thermo Fisher Scientific (TMO) stock movement. Thermo Fisher Scientific stock may have gone up due to positive market sentiment, company performance, economic indicators, or other external factors.
|
| 2024-06-25 | -1.67 % |
|
| 2024-06-24 | +0.24 % |
|
| 2024-06-21 | +1.33 % |
|
| 2024-06-17 | -0.71 % |
|
| 2024-06-11 | -0.96 % |
|
| 2024-06-07 | +0.22 % |
|
| 2024-06-03 | +0.28 % |
- The article discusses the discovery of Styxl2, a pseudophosphatase, which plays a crucial role in sarcomere assembly by promoting the degradation of non-muscle myosins, potentially explaining how sarcomeres correctly assemble in vivo. The recent findings suggest that Styxl2 interacts with non-muscle myosin IIs, enhancing their ubiquitination and autophagy-dependent degradation to facilitate sarcomere assembly. As for why Thermo Fisher Scientific (TMO) stock went up, this is unrelated to the content of the article on Styxl2 and would require checking the latest financial and market news for reasons behind TMO's stock increase.
- Thermo Fisher Scientific (TMO) stock went up by 0.28% following the unveiling of their new Thermo Scientific™ Stellar™ mass spectrometer, a solution that offers fast throughput, high sensitivity, and ease of use for researchers to advance their translational omics research, leading to breakthrough discoveries more efficiently. The stock likely went up as this new technology streamlines the verification of proteins and metabolites of clinical interest, complements the existing workflow, boosts productivity, and achieves higher quantitative sensitivity in analyzing compounds for proteomics, metabolomics, and lipidomics.
|
| 2024-05-28 | -1.97 % |
- The article discusses positive topline results from the ASPEN study conducted by Insmed Incorporated on brensocatib, a potential treatment for patients with bronchiectasis, leading to plans for a New Drug Application (NDA) filing in the fourth quarter of 2024, causing excitement in the market, but despite this positive news, Thermo Fisher Scientific (TMO) stock went down by -1.97% last night; the stock might have gone down due to various market factors, general market sentiment, or company-specific news that may not be directly related to the success of Insmed's brensocatib.
- The article discusses Thermo Fisher Scientific (TMO) and its recent -1.97% stock decrease, attributing it to potential factors like market conditions, company performance, or sector trends, without a specific cause mentioned in the provided text.
- The article discusses Insmed Incorporated's announcement to offer and sell $500 million of shares of its common stock in an underwritten public offering, which might have impacted the stock of Thermo Fisher Scientific. The decrease in Thermo Fisher Scientific stock could be due to market conditions, investor sentiment, or broader economic trends.
|
| 2024-05-23 | -0.98 % |
|
| 2024-05-22 | +0.12 % |
|
| 2024-05-21 | -0.65 % |
|
| 2024-05-17 | -0.31 % |
|
